secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001213900-25-021916
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma provides pipeline update; pre-IND for SPC-15 pending FDA guidance
-----------------------------------------------------------------------------

- Lead asset SPC-15 (intranasal PTSD treatment) aims for first-in-human trials after FDA pre-IND feedback.
- Exclusive global licenses from Columbia University for SPC-15 and SPC-14 (Alzheimer's).
- SP-26 (ketamine implant for fibromyalgia) March 2025 data expected; 505(b)(2) pathway planned.
- SPC-14 (Alzheimer's) and SPU-16 (multiple sclerosis) in preclinical with 2025 data targets.
- Company states sufficient capital resources and no debt to support upcoming catalysts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390025021916/0001213900-25-021916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390025021916/ea0233727-8k_silopharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-021916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer